FDA Regulation in the United States
Breast implants are regulated by the FDA as Class III medical devices — the highest risk category, requiring Premarket Approval (PMA) rather than the simpler clearance pathway used for lower-risk devices. PMA requires clinical trial data demonstrating safety and effectiveness, typically from studies of several hundred to several thousand patients followed for multiple years. Post-approval studies monitoring long-term outcomes are required as conditions of approval. The FDA has approved implants from Allergan (AbbVie), Mentor (Johnson & Johnson), and since 2024, Establishment Labs (Motiva).
European Regulation (CE Marking)
In Europe, breast implants must bear a CE mark under the EU Medical Device Regulation (MDR 2017/745). CE marking indicates conformity with European safety and performance standards, assessed by independent "Notified Bodies." The European regulatory pathway has historically been somewhat less demanding than the FDA's, though the 2017 MDR has significantly strengthened requirements. The PIP implant scandal (2010–2012), in which a French manufacturer used industrial silicone gel rather than medical-grade gel, highlighted gaps in the previous European regulatory framework and drove the stricter MDR.
Post-Approval Surveillance
Both FDA and European regulations require post-approval surveillance — ongoing monitoring of patients with approved implants. This includes voluntary registries (such as the National Breast Implant Registry in the UK), mandatory adverse event reporting, and manufacturer post-approval studies. This surveillance has identified BIA-ALCL risk with textured implants and led to actions including the 2019 Allergan Biocell textured implant recall.
What Regulation Doesn't Guarantee
Regulatory approval confirms that an implant has met defined standards at the time of approval. It does not guarantee the implant will perform without complications for any individual patient, nor does it mean the device is free of all long-term risks. Post-approval surveillance continues to identify new safety signals, as demonstrated by the BIA-ALCL story.
